SNYDrug Approval•globenewswire•
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Sentiment:Positive (70)
Summary
(NASDAQ:SNY) Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 29, 2025 by globenewswire